IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decreased IGFBP-1 expression and increased tumorigenicity

International Journal of Cancer

Volumn 77, Issue 6, 1998, Pages 874-879

  Menouny, Mouna ^a   Binoux, Michel ^a   Babajko, Sylvie ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOGENICITY TESTS; CARCINOMA, SQUAMOUS CELL; DNA PROBES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MICE; MICE, NUDE; TUMOR CELLS, CULTURED;

EID: 0031870764     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980911)77:6<874::AID-IJC13>3.0.CO;2-1     Document Type: Article

References (33)

1. ANGELLOZ-NICOUD, P. and BINOUX, M., Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology, 136, 5485-5492 (1995).
2. BABAJKO, S. and BINOUX, M., Modulation by retinoic acid of insulin-like growth factor (IGF) and IGF binding protein expression in human SK-N-SH neuroblastoma cells. Europ. J. Endocrinol., 134, 474-480 (1996).
3. BABAJKO, S., LENEUVE, P., LORET, C. and BINOUX, M., IGFBP-6 is involved in growth inhibition in SH-SY5Y human neuroblastoma cells. Its production is both IGF- and cell density-dependent. J. Endocrinol., 152, 221-227 (1997).
4. BASERGA, R., HONGO, A., RUBINI, M., PRISCO, M. and VALENTINIS, B., The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. biophys. Acta Rev. Cancer, 1332, F105-F126 (1997).
5. BIRNBAUM, R. and WIREN, K., Changes in insulin-like growth factor-binding protein expression and secretion during the proliferation, differentiation, and mineralization of primary cultures of rat osteoblasts. Endocrinology, 135, 223-230 (1994).
6. BLAT, C., VILLAUDY, J. and BINOUX, M., In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J. clin. Invest., 93, 2286-2290 (1994).
7. CHRISTOFORI, G., NAIK, P. and HANAHAN, D., A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature (Lond.), 369, 414-418 (1994).
8. EL-BADRY, O., ROMANUS, J., HELMAN, L., COOPER, M., RECHLER, M. and ISRAEL, M., Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J. clin. Invest., 84, 829-839 (1989).
9. FLYVBJERG, A., MOGENSEN, O., MOGENSEN, B. and NIELSEN, O., Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J. clin. Endocrinol. Metab., 82, 2308-2313 (1997).
10. GRELLIER, P., DE GALLÉ, B. and BABAJKO, S., Expression of insulin-like growth factor (IGF) binding protein-6 complementary DNA alters neuroblastoma cell growth. Cancer Res. (1998). (In press).
11. HO, P. and BAXTER, R., Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin. Endocrinol., 46, 145-154 (1997).
12. HOEFLICH, A., YANG, Y., HUBER, S., RASCHER, W., KOEPF, G., BLUM, W., HEINZ-ERIAN, P., KOLB, H. and KIESS, W., Expression of IGFBP-2, -3, and -4 mRNA during differentiation of Caco-2 colon epithelial cells. Amer. J. Physiol., 271, E922-E931 (1996).
13. HOSSENLOPP, P., SEGOVIA, B., LASSARE, C., ROGHANI, M., BREDON, M. and BINOUX, M., Evidence of enzymatic degradation of insulin-like growth factor binding protein in the 150 kDa complex during pregnancy. J. clin. Endocrinol. Metab., 71, 791-797 (1990).
14. HOSSENLOPP, P., SEURIN, D., SEGOVIA-QUINSON, B., HARDOUIN, S. and BINOUX, M., Analysis of serum insulin-like growth factor binding proteins using Western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal. Biochem., 154, 138-143 (1986).
15. HUYNH, H., BEAMER, W. and POLLAK, M,. Overexpression of insulin-like growth factor binding protein 4 (IGFBP-4) in MCF-7 breast cancer cells is associated with reduced responsiveness to insulin-like growth factors in vitro and reduced tumour growth in vivo. Int. J. Oncol., 11, 193-197 (1997).
16. JONES, J. and CLEMMONS, D., Insulin-like growth factors and their binding proteins: biological actions. Endocrinol. Rev., 16, 3-34 (1995).
17. JONES, J., GOCKERMAN, A., BUSBY, W., WRIGHT, G. and CLEMMONS, D., Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the a5β1 integrin by means of its Arg-Gly-Asp sequence. Proc. nat. Acad. Sci. (Wash.), 90, 10553-10557 (1993).
18. LALOU,C, SILVE, C., ROSATO, R., SEGOVIA, B. and BINOUX, M., Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology, 135, 2318-2326 (1994).
19. LASSARRE, C. and BINOUX, M., Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology, 134, 1254-1262 (1994).
20. MANIATIS, T., FRITSCH, E.F. and SAMBROOK, J., Extraction, purification, and analysis of mRNA from eukaryotic cells. In: T. Maniatis, E.F. Fritsch and J. Sambrook (eds), Molecular cloning, a laboratory manual, pp. 188-209, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1982).
21. MENOUNY, M., BINOUX, M. and BABAJKO, S., Role of IGFBP-2 and its limited proteolysis in neuroblastoma cell proliferation. Modulation by TGF-β and retinoic acid. Endocrinology, 138, 683-690 (1997).
22. MÜLLER, H., OH, Y., LEHRNBECHER, T., BLUM, W. and ROSENFELD, R., Insulin-like growth factor binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J. clin. Endocrinol. Metab., 79, 428-434 (1994).
23. OH, Y., NAGALLA, S., YAMANAKA, Y., KIM, H.-S., WILSON, E. and ROSENFELD, R., Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. J. biol. Chem., 271, 30322-30325 (1996).
24. RAJAH, R., VALENTINIS, B. and COHEN, P., IGFBP-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J. biol. Chem., 272, 12181-12188 (1997).
25. REEVE, J., SCHWANDER, J. and BLEECHEN, N., IGFBP-2: an important regulator of insulin-like growth factor action in human lung tumours? Growth Regul., 3, 82-84 (1993).
26. ROGLER, C., YANG, D., ROSSETTI, L., DONOHOE, J., ALT, E., CHANG, C., ROSENFELLD, R., NEELY, K. and HINTZ, R., Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J. biol. Chem., 269, 13779-13784 (1994).
27. SAKSELA, K. and RIFKIN, D.B., Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol., 4, 93-126 (1988).
28. SHIMASAKI, S. and LING, N., Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5, and -6). Progr. Growth Factors Res., 3, 243-266 (1991).
29. STEWART, C. and ROTWEIN, P., Growth, differentiation and survival: multiple physiological functions for insulin-like growth factors. Physiol. Rev., 76, 1005-1026 (1996).
30. VILLAUDY, J., DELBE, J., BLAT, C., DESAUTY, G., GOLDE, A. and HAREL, L., An IGF binding protein is an inhibitor of FGF stimulation. J. cell. Physiol., 149, 492-496 (1991).
31. WERNER, H. and LEROITH, D. The role of the insulin-like growth factor system in human cancer. Adv. Cancer Res., 68, 183-223 (1996).
32. WIGLER, M., PELLICER, A., SILVERSTEIN, S., AXEL, R., URLAUB, G. and CHASIN, L., DNA-mediated transfer of the adenine phosphoridosyl transferase locus into mammalian cells. Proc. nat. Acad. Sci. (Wash.), 76, 1373-1376 (1979).
33. ZHANG, L., KASHANCHI, F., ZHAN, Q., ZHAN, S., BRADY, J., FORNACE, A., SETH, P. and HELMAN, L., Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Res., 56, 1367-1373 (1996).